Učitavanje...
IMMU-51. ASSESSING AND AUGMENTING THE IMMUNE RESPONSE TO GLIOBLASTOMA USING REPURPOSED PHARMACEUTICALS
In order to improve the therapeutic responses to immunotherapies in glioblastoma patients, a known pharmaceutical, ritanserin, was repurposed to augment cytotoxic T cell responses and suppress tumor growth. Ritanserin is able to inhibit the activity of diacylglycerol kinase alpha (DGKA), which conve...
Spremljeno u:
| Izdano u: | Neuro Oncol |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2017
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5692415/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.509 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|